Restoring Blood Flow, Renewing Life
Creating new vascular pathways through targeted cell therapy and biomaterial engineering.
Provasctec’s Mission is to Advance the use of Cell Therapies in Regenerative Medicines to Positively Impact Patients’ Lives
As a team of cell biologists, bioengineers, and medical doctors, we enable the delivery of cells to sites of medical need. We focus on mesenchymal stem cells, a cell type with an established safety profile and therapeutic potential across a wide range of diseases.
Provasctec is Unlocking the Therapeutic Potential of Mesenchymal Stem Cells Through Precision Delivery
Mesenchymal stem cells (MSCs) are one of the body’s natural tools for tissue repair and regeneration. They detect and respond to injury, reduce inflammation, modulate the immune response, and secrete growth factors to stimulate repair. MSCs are found in many tissues, such as bone marrow and adipose tissue (fat), making them readily available for large-scale production. They exhibit low immunogenicity, allowing their use in allogenic settings and enabling off-the-shelf products. MSCs have demonstrated a strong safety profile when used in the treatment of a wide range of medical conditions, both critical and benign.
This combination of safety, scalability, and versatility makes MSCs highly suited for therapeutic use.
Technology
Provasctec has Developed a Proprietary Device for Targeted Delivery of Mesenchymal Stem Cells
Past attempts to broadly apply cell therapies have mostly failed to deliver. Key obstacles have been the absence of scalable allogeneic cell sources, effective cell delivery, payload size, and rapid cell death upon delivery.
Our solution intends to overcome historic barriers to cell survival and targeting by combining cells with a biodegradable device that can be delivered to any site in the body. Disease specific design adaptations enable applications across a number of indications, including inflammation, cancer, and other age related diseases.
Through polymer chemistry and structural design we have created a delivery platform which allows any number of cells to be grown outside the body, while tailored preservation protocols support the delivery of a high payload of viable and functional cells to the site of clinical need.
Regenerative Medicines
Precise
Off-the Shelf
Durable Therapy
Lead Program
Critical Limb Ischemia: a Devastating Consequence of Peripheral Artery Disease
Blocked Artery
Precision MSC Delivery
Paracrine Signaling
Neovascular Network Formation
Our Team
Our team combines expertise in stem cell biology, vascular medicine, and interventional technologies, united by the goal of improving outcomes for patients.
Leadership Team
Board Members
Dr. Holger Muller
CEO & Co-Founder
- Scientifically trained, financially educated
- Big Pharma and Start-up C-Suite in product development & commercialization
- Involved in 5 currently marketed pharmaceuticals
Prof. Noel Caplice
CSO & Co-Founder
- Mayo Clinic Trained Interventional Cardiologist
- PhD Vascular Biologist with 30 years Physician Scientist experience
- Serial inventor with first in man clinical trial experience
Dr. Florence Herisson
Group R&D Manager
- PhD in neuroscience
- Expertise in translational large preclinical models
- Proficient in advanced molecular biology techniques, confocal and multi-modal imaging
Dr. Robert Hayes
Technical Scientist
- MSc, PhD in biochemistry and molecular biology
- Experience in GMP and GLP environments
- Proficient in cell culture, cell characterization, process optimization
Dr. Holger Muller
CEO & Co-Founder
- Scientifically trained, financially educated
- Big Pharma and Start-up C-Suite in product development & commercialization
- Involved in 5 currently marketed pharmaceuticals
Prof. Noel Caplice
CSO & Co-Founder
- Mayo Clinic Trained Interventional Cardiologist
- PhD Vascular Biologist with 30 years Physician Scientist experience
- Serial inventor with first in man clinical trial experience
Kevin Dalton
UCC
Kevin Dalton is Commercialisation Manager at UCC Innovation, leading life sciences IP commercialisation and spin-out formation. With 30+ years in the sector and 17 years in tech transfer, he has supported over 15 spinouts that have collectively raised €50M+. Kevin holds an MSc in Biochemistry and advanced qualifications in Corporate Governance and Venture Financing. He is a Registered Technology Transfer Professional (RTTP) and Certified Licensing Professional (CLP). He also serves on the Board of the Irish Technology Transfer Association (IKTA).
- PhD in neuroscience
- Expertise in translational large preclinical models
- Proficient in advanced molecular biology techniques, confocal and multi-modal imaging
Alessandro Radelli
NLC Health
Alessandro Radaelli is an entrepreneur, venture partner, and strategic advisor with extensive experience in building and scaling healthcare businesses across medtech and digital health. He has a strong track record of spotting high-impact opportunities, shaping go-to-market strategies, and guiding startups and new businesses from early concept to commercial success. Before becoming a Venture Partner at NLC Health Ventures, he held senior roles at Philips, where he led complex corporate venture and R&D programs, and helped expand the company’s global clinical and market footprint. Alessandro holds a PhD in Biomedical Sciences from Imperial College London and an executive degree in New Business Development from the Erasmus School of Management in Rotterdam.
- PhD in Biomedical Science
- Extensive experience in scaling healthcare businesses
- Leader of complex corporate venture and R&D programs at Philipps
We collaborate with established leading partner organisations to leverage expertise and existing manufacturing infrastructure.
